Share on

APAC Regenerative Medicine Market Research Report – Segmented By Product, Therapy, Application & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) – Industry Analysis on Size, Share, COVID-19 Impact, Trends & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 245
Pages: 145
Formats: report pdf report excel report power bi report ppt

APAC Regenerative Medicine Market Size (2022 to 2027)

The size of the Asia-Pacific regenerative medicine market is predicted to grow USD 7.89 billion by 2027 from USD 2.22 billion in 2022, showcasing a CAGR of 28.9% from 2022 to 2027.

Stem cells that offer the potential to replace cells and tissues to treat various diseases and disorders, including spinal cord injury, arthritis, and Parkinson's disease, create immense possibilities in APAC regenerative medicine market. Also, stem cell and gene therapy offer a potential treatment for the disease rather than long-term treatment and shift focus from treatment to treatment. Therefore, the application of stem cell technology in disease treatment has ultimately increased adoption rates. Therefore, the growing popularity of stem cell technology and increased research is expected to move the market forward during the forecast period.

Government initiatives supporting advanced therapies, the rising focus of foreign pharmaceutical companies to invest in the Asian healthcare industry, a growing number of patients suffering from chronic disease conditions, and increasing demand for organ transplantation drive the growth of the Asia Pacific Regenerative Medicine Market.

The increasing accidents and bone defects drive the Asia-Pacific (APAC) Regenerative Medicine Market. In addition, some tissue engineering research is also ongoing to develop bone graft substitutes with the help of regenerative medicine. Therefore, with the new development of bone grafts, the market is expected to grow over the forecast period.

However, scarcity of skilled professionals, the low penetration rate of advanced healthcare treatment solutions, and difficulties in maintaining Regenerative Medicine, and the requirement of a high budget for developing cell-based products (such as stem cells) are restraining the growth of the Asia Pacific regenerative medicine market.

This research report on the APAC regenerative medicine market has been segmented and sub-segmented into the following categories:

By Product:

  • Cell-Based Products                            
    • Autologous Cell-Based Products
    • Allogeneic Cell-Based Products  
  • Acellular Products           

By Therapy: 

  • Cell Therapy
  • Gene Therapy
  • Tissue Engineering
  • Immunotherapy

By Application: 

  • Orthopedic & Musculoskeletal Spine                           
  • Dermatology                          
  • Cardiovascular                       
  • Central Nervous System                   
  • Oncology                 
  • Diabetes                  
  • Other Applications

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

The Japanese regenerative medicine market is presently playing a leading role in the Asia Pacific based on the region. In Japan, the Ministry of Health, Labor, and Welfare approved the Regenerative Medicine Act in April 2013, promoting clinical development of regenerative and cell-based therapies as well as; the Chinese government has accepted several studies related to human embryonic stem cells and has encouraged researchers to explore the clinical potential of these cells in China. Also, increasing healthcare needs, changing lifestyles, and aging populations are other factors that positively affect regional market growth. To control the mortality rate during the Covid-19 pandemic, Japanese researchers induced Japanese Encephalitis Vaccine (JEV) to protect the patient especially vulnerable populations like those in morbid condition and elder to tackle the Covid-19. In addition, the rising chronic diseases and cardiovascular diseases will drive growth in the forecast period. Recently the aged population and the population under 18 are capturing more diseases is the challenge. 

The Indian regenerative medicine market is forecasted to grow at a healthy rate between 2020 to 2025. The government of India mainly promotes research and development in regenerative medicine and business development innovations. These organizations assure public empowerment and revolution in healthcare. In this market, challenges remain on achieving regulatory error, feasible outputs, and fair impacts. As per the researchers, a robust social contract is needed to increase participation in the treatments. Also, an authority of private nanomaterials, cord blood banking, and 3D bioprinting required more attention. In the Covid-19 outbreak, there is an increasing demand to develop a new vaccine using regenerative medicine. The research in India concludes that the stem cell repels the viral infection due to interferon-gamma invigorated qualities (ISGs). The growing population and the patients' responses or participants will drive the growth of the regenerative medicine market in India. However, a loosely structured framework of the government will harm the growing market growth. 

The Chinese Regenerative medicine Market size is expected to grow at a CAGR of 29.2% from 2020 to 2025. According to Chinese scientists, patients who have participated in the experiment of Mesenchymal stem cells injections derived from the human umbilical cord can protect the Covid-19 patients. The latter are having dangerous inflammation and severe breathing problems. A growing community of clinical researchers and physicians in China will grow the regional regenerative medicine market by providing treatments like SARS-CoV-2 for such pandemics in the future. However, stringent rules and regulations by the government in approving new drugs are slowly impeding the market demand. In recent days, researchers have immediately launched some clinical trials. The results show that the curative effect of drugs on patients increases; this kind of research will drive the market's growth in the forecast period. 

The recent years for the Australian Regenerative medicine Market were great and predicted to continue throughout the forecast period. Australia stated that the survival rate increased to 83% with mesenchymal stem cells (MSCs) treatment procedures for acute respiratory distress syndrome (ARDS). The Australian regenerative medicine market has the necessary fundaments to become a competitive, profitable, and global industry and extend a big vision towards the future, which will help the regional regenerative medicine market grow in the coming years. However, the high budget requirement for the research is a restraint on this market. It will affect further research studies in the future.

The South Korean Regenerative medicine Market size is expected to foresee a healthy CAGR during the forecast period. South Korea is researching on the Covid-19 places heavy emphasis on regenerative medicine. The system for stem-cell researches in South Korea is less strict than those in other countries. The country is looking to enhance the research and development in regenerative medicine and ensure its regenerative medicine consistency. The government gives funding for research in South Korea is increasing, which is to fuel the market's growth rate. However, the less presence of skilled professionals in the country and the maintenance of regenerative products are threatening market growth.


Noteworthy companies operating in the APAC Regenerative Medicines Market profiled in this report are Vertex Pharmaceuticals Incorporated (U.S.), Acelity L.P. Inc. (U.S.), Celgene Corporation (U.S.), StemCells, Inc. (U.S.), Organogenesis Inc. (U.S.), NuVasive, Inc. (U.S.), Vericel Corporation (Genzyme) (U.S.), Japan Tissue Engineering Co., Ltd. (Japan), Cytori Therapeutics Inc. (U.S.), Advantagene, Inc. (U.S.) and Mesoblast Ltd. (Australia).

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample